Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hydrocodone bitartrate + guaifenesin
- Development stage
- Approved
- Lead developer
- Coastal Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Hydrocodone bitartrate + guaifenesin is a fixed-dose combination pharmaceutical product consisting of the opioid antitussive hydrocodone bitartrate and the expectorant guaifenesin. Hydrocodone acts as a centrally-acting cough suppressant by binding to mu-opioid receptors in the medullary respiratory center, effectively elevating the cough threshold. Guaifenesin functions as an expectorant by increasing the volume and reducing the viscosity of secretions in the trachea and bronchi, thereby facilitating the removal of mucus through ciliary action and coughing. This combination is indicated for the symptomatic relief of non-productive cough and to loosen tenacious mucus associated with the common cold or upper respiratory tract infections in adults aged 18 and older. Due to the presence of hydrocodone, the product is classified as a Schedule II or III controlled substance, carrying significant risks of addiction, abuse, misuse, and respiratory depression.
- Brand names
- FlowtussObredonHycotussKwelcof
- Other names
- hydrocodone and guaifenesinguaifenesin and hydrocodone bitartrate
02
Targets
DOR (Opioid Receptor Delta 1)KOR (Kappa opioid receptor)MOR (Mu opioid receptor)
Beyond the preview
Go deeper on hydrocodone bitartrate + guaifenesin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hydrocodone bitartrate + guaifenesin.